Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LM 108

Next Previous
Drug Profile

LM 108

Alternative Names: LM-108

Latest Information Update: 26 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LaNova Medicines Limited
  • Developer LaNova Medicines Limited; Shanghai Pulmonary Hospital
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Regulatory T-lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Triple negative breast cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 13 Mar 2025 LaNova Medicines Limited plans a phase II trial for Solid tumours (Late-stage disease, Combination therapy, Inoperable/unresectable, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT06873854)
  • 17 Feb 2025 Chia Tai Tianqing Pharmaceutical Group plans a phase Ib/II trial for Adenocarcinoma (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Combination therapy, First-line therapy) in China (IV, Injection), in February 2025 (NCT06821503, LM-108-Ib/II-01-C)
  • 13 Feb 2025 Chia Tai Tianqing Pharmaceutical Group plans a phase I/II trial for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Combination therapy, First-line therapy) in March 2025 (IV, Infusion) (NCT06825494)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top